ROXINDOLE, A DOPAMINE AUTORECEPTOR AGONIST, IN THE TREATMENT OF POSITIVE AND NEGATIVE SCHIZOPHRENIC SYMPTOMS

Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autorec eptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, where as the subgroup with negative symptoms, especially those with the resi dual type of schizophrenia, showed a moderate hut significant 20% redu ction in total scores on the Scale for the Assessment of Negative Symp toms.